Rituximab Plus CAMPATH in Patients With Relapsed/Refractory Low-Grade or Follicular, CD20-positive, B-cell NHL
Clinical trial NCT00077961 · TERMINATED
Trial details
- NCT number
- NCT00077961
- Sponsor
- Genzyme, a Sanofi Company
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2003-12-01
- Primary completion
- 2006-02-01
- Enrollment
- 49
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.